Profile data is unavailable for this security.
About the company
Immatics NV is a clinical-stage biopharmaceutical company that is based in the Netherlands. The Company is focused on the discovery and development of T-Cell eceptors with the goal of enabling a robust and specific T-Cell response against these targets. The Company develops targeted immunotherapies with an emphasis on treating solid tumors through two distinct therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER). Its wholly owned pipeline comprises of eight therapeutic programs, of which four are in clinical trials, including IMA201 (MAGEA4/8), IMA202 (MAGEA1) and ACTolog IMA 101 (Multi-target pilot trial) for solid cancers and IMA203 (PRAME) for hematological and solid cancers, as well as four are in preclinical development, including IMA204 (COL6A3) and IMA401 (Cancer testis antigen) for solid cancers, and ACTallo IMA301 (Cancer testis antigen) and IMA402 (Cancer testis antigen) for hematological and solid cancers.
- Revenue in USD (TTM)100.44m
- Net income in USD-137.32m
- Incorporated2020
- Employees297.00
- LocationImmatics NVPaul Ehrlich-Strasse 15TUEBINGEN 72076GermanyDEU
- Phone+49 70 715397700
- Websitehttps://immatics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Geron Corp | 183.40m | -79.99m | 1.05bn | 229.00 | -- | 4.24 | -- | 5.74 | -0.1202 | -0.1202 | 0.2754 | 0.3896 | 0.3623 | 0.073 | 5.79 | 800,886.40 | -15.80 | -47.39 | -20.34 | -60.65 | 97.70 | -- | -43.61 | -871.15 | 4.87 | -4.25 | 0.4999 | -- | 32,386.92 | 178.45 | 5.19 | -- | 10.49 | -- |
| Inhibrx Biosciences Inc | 1.40m | -155.09m | 1.10bn | 156.00 | -- | -- | -- | 787.44 | -10.02 | -10.02 | 0.0905 | -- | 0.007 | -- | 4.96 | 8,974.36 | -77.54 | 114.91 | -96.94 | 138.28 | -- | -- | -11,077.57 | 4,710.68 | -- | -199.52 | 0.7307 | -- | -88.89 | -56.75 | 799.19 | -- | 7.49 | -- |
| Compass Therapeutics Inc. | 0.00 | -65.81m | 1.12bn | 35.00 | -- | 5.32 | -- | -- | -0.4577 | -0.4577 | 0.00 | 1.18 | 0.00 | -- | -- | 0.00 | -34.60 | -37.49 | -36.20 | -40.90 | -- | -- | -- | -28,561.77 | -- | -- | 0.00 | -- | -- | -- | -16.19 | -- | -37.62 | -- |
| MoonLake Immunotherapeutics | 0.00 | -210.50m | 1.13bn | 100.00 | -- | 3.48 | -- | -- | -3.33 | -3.33 | 0.00 | 4.54 | 0.00 | -- | -- | 0.00 | -45.83 | -- | -50.02 | -- | -- | -- | -- | -- | -- | -43.63 | 0.2021 | -- | -- | -- | -230.31 | -- | -- | -- |
| Savara Inc | 0.00 | -115.65m | 1.14bn | 59.00 | -- | 10.26 | -- | -- | -0.535 | -0.535 | 0.00 | 0.5461 | 0.00 | -- | -- | 0.00 | -60.91 | -36.72 | -66.05 | -39.40 | -- | -- | -- | -109,477.80 | -- | -- | 0.2399 | -- | -- | -- | -75.29 | -- | -29.93 | -- |
| Immatics NV | 100.44m | -137.32m | 1.19bn | 297.00 | -- | 2.42 | -- | 11.89 | -1.13 | -1.13 | 0.8252 | 4.06 | 0.1547 | -- | 27.56 | 338,176.60 | -21.15 | -20.25 | -25.62 | -28.38 | -- | -- | -136.72 | -79.55 | -- | -- | 0.0378 | -- | 188.60 | 53.23 | 116.08 | -- | 49.13 | -- |
| Septerna Inc | 22.05m | -58.81m | 1.23bn | 75.00 | -- | 3.16 | -- | 55.85 | -1.51 | -1.51 | 0.5304 | 8.71 | 0.0565 | -- | 4.98 | 293,933.30 | -15.06 | -- | -16.99 | -- | -- | -- | -266.77 | -- | -- | -- | 0.00 | -- | 611.92 | -- | -12,762.79 | -- | -- | -- |
| Taysha Gene Therapies Inc | 6.31m | -99.93m | 1.25bn | 73.00 | -- | 5.69 | -- | 197.52 | -0.3328 | -0.3328 | 0.0212 | 0.7995 | 0.0254 | -- | -- | 86,438.36 | -40.23 | -70.59 | -45.55 | -88.39 | -- | -- | -1,583.66 | -2,287.96 | -- | -- | 0.1899 | -- | -46.07 | -- | 19.96 | -- | -- | -- |
| AtaiBeckley Inc | 3.02m | -154.19m | 1.30bn | 54.00 | -- | 5.37 | -- | 428.91 | -0.8136 | -0.8136 | 0.0161 | 0.6644 | 0.0138 | -- | 0.3354 | 55,981.48 | -70.56 | -45.69 | -77.07 | -50.03 | -- | -- | -5,104.20 | -2,658.81 | -- | -- | 0.00 | -- | -1.91 | -- | -271.09 | -- | 37.97 | -- |
| Monte Rosa Therapeutics Inc | 181.54m | 20.95m | 1.31bn | 147.00 | 71.52 | 4.50 | 44.63 | 7.20 | 0.2506 | 0.2506 | 2.20 | 3.98 | 0.4685 | -- | 65.30 | 1,354,761.00 | 5.41 | -33.14 | 6.24 | -39.19 | -- | -- | 11.54 | -563.84 | -- | -- | 0.00 | -- | -- | -- | 46.29 | -- | 23.56 | -- |
| Azenta Inc | 594.95m | 28.69m | 1.32bn | 3.00k | 45.77 | 0.768 | 15.43 | 2.22 | 0.6252 | -1.26 | 12.98 | 37.26 | 0.2891 | 4.03 | 4.00 | 198,317.70 | 1.39 | -0.3901 | 1.57 | -0.4328 | 44.59 | 45.32 | 4.82 | -1.73 | 2.61 | -- | 0.00 | -- | 3.55 | 8.85 | 200.38 | -- | -3.24 | -- |
| Rapport Therapeutics Inc | 0.00 | -97.70m | 1.33bn | 69.00 | -- | 2.60 | -- | -- | -2.71 | -2.71 | 0.00 | 10.74 | 0.00 | -- | -- | 0.00 | -22.55 | -- | -23.12 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -125.11 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -45.86m | 1.33bn | 26.00 | -- | 7.03 | -- | -- | -0.3713 | -0.3713 | 0.00 | 1.48 | 0.00 | -- | -- | 0.00 | -34.19 | -45.07 | -36.67 | -51.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -64.84 | -- | 31.21 | -- |
Data as of Feb 13 2026. Currency figures normalised to Immatics NV's reporting currency: US Dollar USD
61.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| T. Rowe Price Investment Management, Inc.as of 30 Sep 2025 | 19.38m | 14.46% |
| Baker Bros. Advisors LPas of 30 Sep 2025 | 12.09m | 9.02% |
| Suvretta Capital Management LLCas of 30 Sep 2025 | 12.03m | 8.97% |
| Perceptive Advisors LLCas of 30 Sep 2025 | 9.38m | 7.00% |
| RTW Investments LPas of 30 Sep 2025 | 8.82m | 6.58% |
| Vestal Point Capital LPas of 30 Sep 2025 | 6.35m | 4.74% |
| Cowen Financial Products LLCas of 30 Sep 2025 | 5.12m | 3.82% |
| Jefferies Investment Advisers LLCas of 31 Dec 2025 | 5.06m | 3.77% |
| Morgan Stanley & Co. LLCas of 31 Dec 2025 | 2.08m | 1.55% |
| Woodline Partners LPas of 30 Sep 2025 | 1.84m | 1.37% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
